BRPI0517091A - composto, e, método para tratar uma doença ou condição alterando-se uma resposta mediada por um receptor de opióide - Google Patents
composto, e, método para tratar uma doença ou condição alterando-se uma resposta mediada por um receptor de opióideInfo
- Publication number
- BRPI0517091A BRPI0517091A BRPI0517091-5A BRPI0517091A BRPI0517091A BR PI0517091 A BRPI0517091 A BR PI0517091A BR PI0517091 A BRPI0517091 A BR PI0517091A BR PI0517091 A BRPI0517091 A BR PI0517091A
- Authority
- BR
- Brazil
- Prior art keywords
- disease
- treating
- condition
- altering
- opioid receptor
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 230000001404 mediated effect Effects 0.000 title abstract 2
- 102000003840 Opioid Receptors Human genes 0.000 title 1
- 108090000137 Opioid Receptors Proteins 0.000 title 1
- 206010012335 Dependence Diseases 0.000 abstract 1
- 229940035676 analgesics Drugs 0.000 abstract 1
- 239000000730 antalgic agent Substances 0.000 abstract 1
- 229940125681 anticonvulsant agent Drugs 0.000 abstract 1
- 239000001961 anticonvulsive agent Substances 0.000 abstract 1
- 229940125714 antidiarrheal agent Drugs 0.000 abstract 1
- 239000003793 antidiarrheal agent Substances 0.000 abstract 1
- 125000003917 carbamoyl group Chemical class [H]N([H])C(*)=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- CYEBJEDOHLIWNP-UHFFFAOYSA-N methanethioamide Chemical compound NC=S CYEBJEDOHLIWNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/22—Bridged ring systems
- C07D221/26—Benzomorphans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/22—Bridged ring systems
- C07D221/28—Morphinans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
- C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
- C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
- C07D489/08—Oxygen atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
COMPOSTO, E, MéTODO PARA TRATAR UMA DOENçA OU CONDIçãO ALTERANDO-SE UMA RESPOSTA MEDIADA POR UM RECEPTOR DE OPIóIDE. 4-hidroxibenzomorfanos contendo carboxamida ou tiocarboxamida na posição-3, são usados como analgésicos, agentes antidiarréicos, anticonvulsivos, antitussigenos e medicamentos anti-adicção.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62534804P | 2004-11-05 | 2004-11-05 | |
US60/625,348 | 2004-11-05 | ||
PCT/US2005/039911 WO2006052710A1 (en) | 2004-11-05 | 2005-11-03 | 4-hydroxybenzomorphans |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI0517091A true BRPI0517091A (pt) | 2008-09-30 |
BRPI0517091B1 BRPI0517091B1 (pt) | 2019-10-08 |
BRPI0517091B8 BRPI0517091B8 (pt) | 2021-05-25 |
Family
ID=36128632
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0517091A BRPI0517091B8 (pt) | 2004-11-05 | 2005-11-03 | composto 4-hidroxibenzomorfano substituído na posição-3 por carboxamida ou tiocarboxamida |
Country Status (20)
Country | Link |
---|---|
US (7) | US7262298B2 (pt) |
EP (2) | EP1817291A1 (pt) |
JP (3) | JP5198067B2 (pt) |
KR (1) | KR101115841B1 (pt) |
CN (1) | CN101090891B (pt) |
AT (1) | ATE557006T1 (pt) |
AU (1) | AU2005304950B2 (pt) |
BR (1) | BRPI0517091B8 (pt) |
CA (1) | CA2587074C (pt) |
CY (1) | CY1112946T1 (pt) |
DK (1) | DK2251330T3 (pt) |
ES (1) | ES2387737T3 (pt) |
IL (1) | IL182983A (pt) |
MX (1) | MX2007005389A (pt) |
NO (1) | NO340204B1 (pt) |
PL (1) | PL2251330T3 (pt) |
PT (1) | PT2251330E (pt) |
RU (2) | RU2480455C2 (pt) |
SI (1) | SI2251330T1 (pt) |
WO (1) | WO2006052710A1 (pt) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1944292B9 (en) | 2000-10-31 | 2016-07-06 | Rensselaer Polytechnic Institute | 8-substituted-2,6-methano-3-benzazocines and 3-substituted morphinanes as opioid receptor binding agents |
EP1817291A1 (en) * | 2004-11-05 | 2007-08-15 | Rensselaer Polytechnic Institute | 4-hydroxybenzomorphans |
US7557119B2 (en) | 2005-07-21 | 2009-07-07 | Rensselaer Polytechnic Institute | Large substituent, non-phenolic opioids |
DE602008004245D1 (de) | 2007-05-04 | 2011-02-10 | Mallinckrodt Inc | Verbessertes verfahren zur herstellung von 6-alpha-hydroxy-n-alkylierten opiaten |
EP2167505B1 (en) | 2007-07-17 | 2012-11-28 | Mallinckrodt LLC | Preparation of n-alkylated opiates by reductive amination |
BRPI0815020A2 (pt) | 2007-08-09 | 2015-03-10 | Rensselaer Polytech Inst | Composto, e, métodos de aliviar um efeito colateral de um opiato em um paciente que recebeu um opiato, e de melhorar função do intestino pós-operatório em um paciente que se submeteu a cirurgia. |
AU2009300392B2 (en) | 2008-09-30 | 2014-10-23 | SpecGx LLC | Processes for the selective amination of ketomorphinans |
US8946419B2 (en) | 2009-02-23 | 2015-02-03 | Mallinckrodt Llc | (+)-6-hydroxy-morphinan or (+)-6-amino-morphinan derivatives |
EP3170395A1 (en) * | 2009-03-19 | 2017-05-24 | Alkermes Pharma Ireland Limited | Morphinan derivatives with high oral bioavailability |
US20100261906A1 (en) * | 2009-04-09 | 2010-10-14 | Mallinckrodt Inc. | Preparation of 6-Keto, 3-Alkoxy Morphinans |
US8471023B2 (en) | 2009-06-11 | 2013-06-25 | Mallinckrodt Llc | Reductive amination of 6-keto normorphinans by catalytic hydrogen transfer |
WO2010144641A1 (en) | 2009-06-11 | 2010-12-16 | Mallinckrodt Inc. | Preparation of 6-alpha-amino n-substituted morphinans by catalytic hydrogen transfer |
TR201908514T4 (tr) * | 2009-12-04 | 2019-07-22 | Alkermes Pharma Ireland Ltd | İlaç doz aşimi tedavi̇si̇ i̇çi̇n morfi̇nan türevleri̇ |
JP5964809B2 (ja) | 2010-03-22 | 2016-08-03 | レンセラール ポリテクニック インスティチュート | オピオイド受容体リガンドとしてのカルボキサミド基を含有するモルヒネ誘導体 |
ES2527315T3 (es) | 2010-04-29 | 2015-01-22 | Mallinckrodt Llc | Preparación de compuestos morfinano con cetona saturada que tienen un bajo contenido en metal |
ES2708726T3 (es) | 2010-07-08 | 2019-04-10 | Alkermes Pharma Ireland Ltd | Proceso para la síntesis de morfinanos sustituidos |
US8778960B2 (en) | 2010-08-23 | 2014-07-15 | Alkermes Pharma Ireland Limited | Methods for treating antipsychotic-induced weight gain |
WO2012138888A1 (en) | 2011-04-05 | 2012-10-11 | Alkermes, Inc. | Process for the synthesis of quaternary amine compounds |
ES2698408T3 (es) | 2011-06-09 | 2019-02-04 | SpecGx LLC | Aminación reductora de 6-ceto morfinanos por transferencia de hidrógeno catalítico |
EP2725908B1 (en) | 2011-06-29 | 2017-05-31 | Alkermes, Inc. | Peripherally acting opioid compounds |
EP2753622B1 (en) | 2011-09-08 | 2016-01-20 | Mallinckrodt LLC | Production of alkaloids without the isolation of intermediates |
PL3153171T3 (pl) | 2011-12-15 | 2019-02-28 | Alkermes Pharma Ireland Limited | Samidorfan (alks 33) w połączeniu z buprenorfiną do leczenia zaburzeń depresyjnych |
US9211293B2 (en) | 2011-12-15 | 2015-12-15 | Alkermes Pharma Ireland Limited | Opioid agonist antagonist combinations |
AU2014268361B2 (en) | 2013-05-24 | 2018-09-06 | Alkermes Pharma Ireland Limited | Morphan and morphinan analogues, and methods of use |
EP3003311A2 (en) | 2013-05-24 | 2016-04-13 | Alkermes Pharma Ireland Limited | Methods for treating depressive symptoms |
CA3054122A1 (en) * | 2017-03-02 | 2018-09-07 | Sanwa Kagaku Kenkyusho Co., Ltd. | Therapeutic agent for alcohol use disorders |
CN107089948B (zh) * | 2017-04-28 | 2020-07-17 | 云南大学 | 吗吩衍生物及其制备方法和应用 |
CN111978252A (zh) * | 2019-05-21 | 2020-11-24 | 复旦大学 | 手性苯并吗吩烷类衍生物及其制备方法和在药学上的应用 |
TW202140009A (zh) * | 2020-02-13 | 2021-11-01 | 大陸商上海翰森生物醫藥科技有限公司 | 3-甲醯胺基-4-羥基納曲酮氘代衍生物、其製備方法及其在醫藥上的應用 |
CN111205151B (zh) * | 2020-02-29 | 2021-03-05 | 深圳市祥根生物科技有限公司 | 一种布洛芬杂质i的环保制备方法 |
EP4243768A1 (en) | 2020-11-12 | 2023-09-20 | Alkermes Pharma Ireland Limited | Immediate release multilayer tablet |
KR102663533B1 (ko) * | 2021-11-09 | 2024-05-08 | 백미선 | 레이저 치료기기용 온냉각장치 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4032529A (en) * | 1974-09-20 | 1977-06-28 | Sterling Drug Inc. | Aminomethanobenzazocine intermediates |
US3957793A (en) * | 1974-09-20 | 1976-05-18 | Sterling Drug Inc. | Hydroxyiminobenzazocines |
US4205171A (en) * | 1976-01-12 | 1980-05-27 | Sterling Drug Inc. | Aminomethanobenzazocines and nitromethanobenzazocines |
US4373139A (en) * | 1979-04-30 | 1983-02-08 | Motorola, Inc. | Detectors |
US4649200A (en) * | 1986-05-08 | 1987-03-10 | Regents Of The University Of Minnesota | Substituted pyrroles with opioid receptor activity |
EP0632041A1 (en) | 1993-07-01 | 1995-01-04 | Katholieke Universiteit Nijmegen | New morphine derivatives having improved analgesic and narcotic properties |
PL327943A1 (en) | 1996-01-10 | 1999-01-04 | Smithkline Beecham Spa | Condensed heterocyclic derivatives of morphonoide (ii) |
EP1944292B9 (en) | 2000-10-31 | 2016-07-06 | Rensselaer Polytechnic Institute | 8-substituted-2,6-methano-3-benzazocines and 3-substituted morphinanes as opioid receptor binding agents |
WO2004007449A1 (en) | 2002-07-16 | 2004-01-22 | Rensselaer Polytechnic Institute | Process for conversion of phenols to carboxamides via the succinimide esters |
EP1817291A1 (en) * | 2004-11-05 | 2007-08-15 | Rensselaer Polytechnic Institute | 4-hydroxybenzomorphans |
-
2005
- 2005-11-03 EP EP05851351A patent/EP1817291A1/en not_active Withdrawn
- 2005-11-03 RU RU2010147915/04A patent/RU2480455C2/ru active
- 2005-11-03 AU AU2005304950A patent/AU2005304950B2/en active Active
- 2005-11-03 MX MX2007005389A patent/MX2007005389A/es active IP Right Grant
- 2005-11-03 WO PCT/US2005/039911 patent/WO2006052710A1/en active Application Filing
- 2005-11-03 EP EP10008474A patent/EP2251330B1/en active Active
- 2005-11-03 US US11/266,651 patent/US7262298B2/en active Active
- 2005-11-03 KR KR1020077012582A patent/KR101115841B1/ko active IP Right Grant
- 2005-11-03 PT PT10008474T patent/PT2251330E/pt unknown
- 2005-11-03 RU RU2007120759/04A patent/RU2415131C2/ru active
- 2005-11-03 CN CN2005800451698A patent/CN101090891B/zh active Active
- 2005-11-03 BR BRPI0517091A patent/BRPI0517091B8/pt active IP Right Grant
- 2005-11-03 PL PL10008474T patent/PL2251330T3/pl unknown
- 2005-11-03 JP JP2007540055A patent/JP5198067B2/ja active Active
- 2005-11-03 ES ES10008474T patent/ES2387737T3/es active Active
- 2005-11-03 SI SI200531549T patent/SI2251330T1/sl unknown
- 2005-11-03 AT AT10008474T patent/ATE557006T1/de active
- 2005-11-03 DK DK10008474.8T patent/DK2251330T3/da active
- 2005-11-03 CA CA2587074A patent/CA2587074C/en active Active
-
2007
- 2007-05-03 IL IL182983A patent/IL182983A/en active IP Right Grant
- 2007-06-04 NO NO20072839A patent/NO340204B1/no unknown
- 2007-06-08 US US11/760,039 patent/US8680112B2/en active Active
-
2012
- 2012-07-31 CY CY20121100677T patent/CY1112946T1/el unknown
- 2012-11-22 JP JP2012256445A patent/JP6058981B2/ja active Active
-
2013
- 2013-04-15 US US13/862,975 patent/US20130231361A1/en not_active Abandoned
-
2014
- 2014-01-31 US US14/169,305 patent/US8802655B2/en active Active
- 2014-07-02 US US14/321,885 patent/US20150011768A1/en not_active Abandoned
-
2015
- 2015-04-27 US US14/697,013 patent/US20160075658A1/en not_active Abandoned
- 2015-08-12 JP JP2015159733A patent/JP2016020364A/ja active Pending
-
2023
- 2023-04-17 US US18/301,336 patent/US20240092740A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0517091A (pt) | composto, e, método para tratar uma doença ou condição alterando-se uma resposta mediada por um receptor de opióide | |
CY1121135T1 (el) | Ενωσεις υποκατεστημενης τετρακυκλιnhς για την θεραπευτικη αγωγη φλεγμονωδων διαταραχων του δερματος | |
ZA200502247B (en) | Selected CGRP antagonists, method for production and use thereof as medicament. | |
ATE469895T1 (de) | Cgrp-rezeptorantagonisten | |
RS50660B (sr) | Dihidrotetrabenazini i farmaceutske kompozicije koje ih sadrže | |
WO2005079756A3 (en) | Combination of a nmda receptor antagonist and an anti-depressive drug mao-inhibitor or a gadph-inhibitor for the treatment of psychiatric conditions | |
TW200738270A (en) | Method of treating depression using a TNFα antibody | |
CL2007003265A1 (es) | Compuestos derivados de 1h-piran[2,3-d]pirimidin-2,4,7-triona; y composicion farmaceutica, util para el tratamiento de sindrome metabolico, dislipidemia y enfermedades cardiovasculares entre otras. | |
NO20052496D0 (no) | Selekterte CGRP antagonister, fremgangsmater for fremstilling derav og anvendelse derav som medikamenter. | |
WO2007073497A3 (en) | Calcium channel antagonists | |
ECSP077360A (es) | Compuestos sulfonamida | |
ATE402928T1 (de) | Sulphonamidverbindungen, die die chemokinrezeptoraktivität (ccr4) modulieren | |
EP2101772A4 (en) | NEUROMUSCULAR BLOCKAGE AGENTS WITH INTERMEDIATE DURATION AND THEIR ANTAGONISTS | |
BRPI0607351A2 (pt) | métodos para tratamento de linfomas empregando uma combinação de agente quimioterapêutico e il-2 e opcionalmente um anticorpo anti-cd20 | |
EA200900767A1 (ru) | Антагонистические антитела против ephb3 | |
FR2886851B1 (fr) | Composition a base d'une avermectine et de metronidazole notamment pour le traitement de la rosacee | |
BRPI0718469A2 (pt) | Uso de um antagonista de interleucina 1 (il-1), método para tratar, inibir, ou melhorar pseudogota, uso de um ou mais agentes terapêuticos, e, produto. | |
DE502005004128D1 (de) | Alkaloidhaltiges futtermittel bzw. futtermittelzusatz | |
CR8009A (es) | Compuestos benzo[1,2,5] tiadiazoles | |
MY142214A (en) | Prophylactic or therapeutic agent for depression or anxiety disorder | |
DK1220852T3 (da) | Substituerede diazepaner | |
FR2886852B1 (fr) | Composition a base d'une avermectine et d'hydrocortisone notamment pour le traitement de la rosacee | |
WO2006129867A3 (en) | ENHANCED EXPRESSION OF LACTOFERRIN mRNA BY LACRITIN | |
ITMO20020069A1 (it) | Profumatore, con raccogligocce, per autoveicoli | |
MX2009003441A (es) | Agonistas del receptor de eritropoyetina humana, composiciones, metodos y usos para prevenir o tratar condiciones relacionadas con la intolerancia a la glucosa. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 08/10/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 08/10/2019, OBSERVADAS AS CONDICOES LEGAIS |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/11/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
B15V | Prolongation of time limit allowed |